Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ocata Therapeutics Inc (OCAT)

Ocata Therapeutics Inc (OCAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ocata Therapeutics Inc 33 LOCKE DRIVE MARLBOROUGH MA 01752

www.ocata.com P: 508-756-1212

Description:

Ocata Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata focuses on the development of methods to generate replacement cells from both human embryonic and adult stem cells. The Company's most advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata Therapeutics, Inc., formerly known as named Advanced Cell Technology, is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 357,860
Shares Outstanding, K 42,230
Annual Sales, $ 160 K
Annual Net Income, $ -34,750 K
Last Quarter Sales, $ 80 K
Last Quarter Net Income, $ -3,850 K
60-Month Beta 0.53
% of Insider Shareholders 3.64%
% of Institutional Shareholders 14.66%

Growth:

1-Year Return 31.32%
3-Year Return 11.89%
5-Year Return -52.68%
5-Year Revenue Growth -75.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 02/15/16
Earnings Per Share ttm -0.58
EPS Growth vs. Prev Qtr 10.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-100 on 08/28/14

OCAT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -454.71%
Return-on-Assets % -147.65%
Profit Margin % -21,718.75%
Debt/Equity 0.41
Price/Sales 1,287.06
Price/Cash Flow N/A
Price/Book 25.99
Book Value/Share 0.33
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar